… The genomic examination of breast cancer includes testing … multiple copy number abnormalities
across the genome. The … aimed at evaluating the genome-wide status of chromosomal …

… For the practical implementation of personalized BC therapies, proper evaluation and … (erbB2)
belongs to the EGFR family of tyrosine kinases and is located on chromosome 17 (17q12). …

… 2 (HER2/ERBB2)– positive breast cancer. We aimed to study … and tumor response and to
evaluate biomarkers that could … , the HER2 gene, and chromosome 17 centromere (CEN17) in …

… ERBB2 gene has been implicated in the development of gastric adenocarcinoma. However,
unlike in breast cancer, the prognostic significance of HER2 status in … is evaluated by IHC to …

… of low ERBB2 protein expression in breast cancer tissue. … The assessment of HER2 status
in breast cancer: the past, the … 2 (HER2) gene amplification in breast cancer specimens. Diagn …

… reducing cancer progression, which can be seen in breast cancer… for chromosome 17 copies
and cancers with more than one … , HER2 status in cancers can be tested in different cancers …

… status, BRCA1/2 mutation status, ERBB2 amplification status) or … derangements in the long
arm of chromosome 17 [49, 50], … models for individualized risk assessment, and models that …

… PTEN protein loss, evaluated by measuring protein status by … Due to AKT gene activation
in many types of cancer and its … in various cancers, an analysis of AKT gene abnormalities in …

… abnormalities in human and canine samples to evaluate the canine model’s validity for breast
cancer … However, certain genes like TP53, EGFR, ERBB2, ATM and CHEK2 show lower …

… we evaluated the capacity of Rlip knockout to prevent breast … of genes related to breast
cancer by qRT-PCR in breast tumors … methylation abnormalities in the p53-null mice. That anti-…